大环内酯类抗生素专利申请状况分析

Analysis of Patent Application Status of Macrolide Antibiotics

本文对大环内酯类抗生素专利申请数据进行统计分析,发现我国大环内酯类抗生素专利申请量不断增加,但申请质量与发达国家还有不小的差距,核心专利基本掌握在国外大公司手中,但我国有望通过第三代大环内酯类抗生素可利霉素打破技术封锁。

Based on the statistical analysis of the patent application data of macrolide antibiotics,it is found that the number of patent applications of macrolide antibiotics in China is increasing,but the quality of application is still far behind that of developed countries.The core patents are basically in the hands of large foreign companies,but China is expected to break the technical blockade through the third generation of macrolide antibiotics,kelimycin.